NOT-CA-08-005: Expansion of Scientific Scope of PAR-08-025, Quick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants (R21), to Include Symptom Management

Expansion of Scientific Scope of PAR-08-025, Quick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants (R21), to Include Symptom Management

Notice Number: NOT-CA-08-005

Key Dates
Release Date: December 27, 2007

Issued by
National Cancer Institute (NCI) (http://www.nci.nih.gov)

The purpose of this Notice is to inform prospective applicants that the programmatic scope of the Program Announcement PAR-08-025 “Quick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants (R21)” is expanded to include (and encourage) research projects related to managing symptoms associated with cancer and its treatment.

To reflect this scope expansion, the specified below passages in PAR-08-025 are appended as indicated by highlighted text:

Executive Summary (the 5th sentence in the “Purpose” bullet): “Applications that explore complementary and alternative approaches for cancer prevention, treatment, and/or symptom management are also encouraged.”

Research Objectives (Purpose section): “The major purpose of this funding opportunity announcement (FOA) is to expedite clinical translation of basic research discoveries in cancer biology and cancer symptom management, through the development of novel anti-cancer and symptom reducing drugs, diagnostic tools, treatments, and preventions.”

Research Objectives (the last two sentences of Background section): “This FOA is intended to stimulate clinical translational research and accelerate the process of targeted cancer drug development for the treatment and prevention of cancer and the management of cancer symptoms associated with various disease stages and toxicities/adverse effects associated with different interventions. In addition, applications that explore complementary and alternative approaches for cancer prevention, treatment, and symptom management are also encouraged.”

Except for the above expansion of the scientific scope, all the other aspects of PAR-08-025 remain unchanged.

Inquiries

Direct questions regarding this expansion of scope to:

Ann M. O'Mara, Ph.D., R.N., F.A.A.N.
Community Oncology and Prevention Trials Research Group
Division of Cancer Prevention
National Cancer Institute
6130 Executive Boulevard, EPN Room 2010, MSC 7328
Bethesda, MD 20892-7328 (for U.S. Postal Service express or regular mail)
Rockville, MD 20852 (for non-USPS delivery)
Telephone: 301-496-8541
Fax: 301-496-8667
Email: [email protected]